Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 11/20 | 0.55 |
| ▸ | EGFR | P00533 | 6/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.54 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | BCR | P11274 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1898838 | 1.00 | SRC (0.55) | SRCEGFRERBB2MAP2K1ABL1 | |
| SCHEMBL4950543 | 0.94 | SRC (0.55) | SRCEGFRERBB2MAP2K1ABL1 | |
| SCHEMBL4986768 | 0.90 | SRC (0.52) | SRCEGFRERBB2MAP2K1ABL1 | |
| SCHEMBL1893090 | 0.88 | SRC (0.62) | SRCEGFRERBB2ABL1BCR | |
| SCHEMBL29590073 | 0.88 | SRC (0.62) | SRCEGFRERBB2ABL1BCR | |
| SCHEMBL4741688 | 0.84 | MAP2K1 (0.54) | SRCEGFRERBB2MAP2K1 | |
| SCHEMBL5740934 | 0.84 | SRC (0.58) | SRCEGFRERBB2ABL1BCR | |
| SCHEMBL5740938 | 0.84 | SRC (0.58) | SRCEGFRERBB2ABL1BCR | |
| SCHEMBL13671174 | 0.84 | SRC (0.43) | SRCEGFRERBB2MAP2K1ABL1 | |
| SCHEMBL2965914 | 0.83 | SRC (0.55) | SRCEGFRERBB2ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11883367-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-30 | — | — | US | disclosed |
| US-20230071711-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-09 | — | — | US | disclosed |
| US-11318157-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11318157-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | SRC 1585/4885EGFR 3324/4885ERBB2 2712/4885 |
| US-20230071711-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT6, PRMT1 | SRC 2133/4885EGFR 3963/4885ERBB2 3240/4885 |
| US-11883367-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | SRC 1800/4885EGFR 3600/4885ERBB2 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.